This week in our colorectal cancer mini-series we have covered the validation of Immunoscore as a tool for determining which patients have high T cells in their tuours and are therefore candidates for single agent immunotherapy (Link), as well as microsatellite instability (MSI) and mismatch-repair deficient tumours and how they can respond immunotherapy (Link).
What happens in the majority (95%) of patients, the microsatellite stable (MSS) disease who are mismatch-repair proficient though? They don’t respond well to checkpoint blockade so how can we help them?
In Chicago, BSB interviewed Dr Johanna Bendell from the Sarah Cannon Research Institute in Nashville, Tennessee to find out more about what she and her colleagues have been doing and where they plan to go next.
You can learn about her perspectives from ASCO by logging in or if you’re new then you can sign up for a BSB subscription…